Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway
Cellular Oncology · 2023
DOI: 10.1007/s13402-023-00822-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Oncology, 2023. Verfasst von Yiyi Ji und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. Hauptthemen laut MEDLINE: Ketotifen, Prostatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ren Ji Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Neuroendocrine prostate cancer (NEPC), a highly aggressive subtype of prostate cancer displaying resistance to hormone therapy, presents a poor prognosis and limited therapeutic options. Here, we aimed to find novel medication therapies for NEPC and explore the underlying mechanism. METHODS: A high-throughput drug screening utilizing an FDA-approved drug library was performed and ketotifen, an antihistamine agent, was identified as a potential therapeutic candidate for NEPC. The whole-transcriptome sequencing analysis was conducted to explore mechanism of ketotifen inhibitory in NEPC. Multiple cell biology and biochemistry experiments were performed to confirm the inhibitory effect of ketotifen in vitro. A spontaneous NEPC mice model (PBCre4:Ptenf/f;Trp53f/f;Rb1f/f) was used to reveal the inhibitory effect of ketotifen in vivo. RESULTS: Our in vitro experiments demonstrated that ketotifen effectively suppressed neuroendocrine differentiation, reduced cell viability, and reversed the lineage switch via targeting the IL-6/STAT3 pathway. Our in vivo results showed that ketotifen significantly prolonged overall survival and reduced the risk of distant metastases in NEPC mice model. CONCLUSION: Our findings repurpose ketotifen for antitumor applications and endorse its clinical development for NEPC therapy, offering a novel and promising therapeutic strategy for this formidable cancer subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China.
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. yinjiezhu@outlook.com.
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. wqi@sjtu.edu.cn.
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China. wqi@sjtu.edu.cn.
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. uroxuewei@163.com.
Förderung
- Ren Ji Hospital
- National Natural Science Foundation of China
Zitieren
APA
Ji, Y., Liu, B., Chen, L., Li, A., Shen, K., Su, R., Zhang, W., Zhu, Y., Wang, Q., & Xue, W. (2023). Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cellular Oncology. https://doi.org/10.1007/s13402-023-00822-9
Vancouver
Ji Y, Liu B, Chen L, Li A, Shen K, Su R, et al. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cellular Oncology. 2023. doi:10.1007/s13402-023-00822-9
BibTeX
@article{Ji2023,
author = {Ji, Yiyi and Liu, Bo and Chen, Lei and Li, Ang and Shen, Kai and Su, Ruopeng and Zhang, Weiwei and Zhu, Yinjie and Wang, Qi and Xue, Wei},
title = {Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway},
journal = {Cellular Oncology},
year = {2023},
doi = {10.1007/s13402-023-00822-9}
}
EUVIMED